Top NYC, NY Social Impact Companies With Best Stability & Growth (263)

Investor Backing & Capital Strength: Successive up-rounds (Series C in 2023 and Series D in 2024) with a marked valuation step-up indicate strong investor conviction and ample capital for expansion. Feedback suggests this funding underpins continued product investment and nationwide scaling.

Market Expansion: The platform reports activity in all 50 states and D.C., rising provider and patient counts, and expansion into Medicare Advantage and Medicaid. Help-center updates and company materials highlight broader coverage and multi‑state credentialing enabling nationwide reach.

Strategic Partnerships: Participation with major insurers (e.g., Aetna, select BCBS plans, Cigna/Evernorth, UnitedHealthcare/Optum) and support from partners like BCBS Massachusetts signal strong payer alignment. These relationships appear to facilitate national scale and access across plan types.

Strong Revenue Growth: Company disclosures indicate Hinge’s direct revenue rose steadily through late 2025 and continued to increase in early 2026. Portfolio commentary links recent outperformance in part to Hinge’s sustained momentum.

Market Expansion: Hinge broadened its footprint across Europe and into Latin America and India, achieving top download ranks in targeted European countries and quickly reaching high positions in Mexico and Brazil. Management outlines continued international rollouts with organic traction preceding full marketing.

Innovation-Driven Growth: The app introduced verification and conversation tools (e.g., Face Check, Convo Starters) that are reported to improve outcomes and safety while supporting monetization. Its “intentional dating” positioning aligns product features with higher‑intent engagement.

Investor Backing & Capital Strength: Company communications and ownership updates indicate full acquisition by a long‑term strategic investor, with messaging about continued support for product and go‑to‑market investment. This backing is framed as enabling the next phase of growth.

Product Line Growth: Public materials highlight ongoing feature releases, expanded offerings like a middle‑school science solution, and updated efficacy positioning aligned to funding pathways. These updates suggest an expanding portfolio aimed at deeper district use.

Strong Market Position & Advantage: Go‑to‑market messaging emphasizes broad U.S. district presence, district‑wide subscription focus, and inclusion on large‑district vendor lists. Continued hiring and major conference activity point to sustained market engagement at scale.

Market Expansion: Public materials indicate the network has expanded to 6,000+ research sites across 50+ countries and 25+ sponsors, up from 5,500+ sites cited in late 2025. This footprint growth signals broader geographic reach and increasing demand-side participation.

Strategic Partnerships: Announced partnerships such as the September 2025 RealTime eClinical data-integration open access to 50+ large site networks (2,000+ sites) and enrich marketplace data. Additional integrations (e.g., eClinPro in 2026) reinforce distribution and embed the platform more deeply in site workflows.

Innovation-Driven Growth: The company launched AI-enabled pre-screening, AI site selection, and EHR integration in 2025–2026 to improve patient identification and sponsor decision-making. These capabilities can increase conversion and make the platform more attractive to both sites and sponsors.

Investor Backing & Capital Strength: Recent Series A and Series B financings are cited to fund product development and scale to larger institutions, signaling runway and investor confidence.

Strong Revenue Growth: Company materials and coverage indicate revenues, client count, and monthly accounts have increased meaningfully since the 2022 Series A.

Diversified Customer Base: Named relationships span large credit unions, fintech lenders, banks, card issuers, and debt buyers, suggesting broad enterprise traction across creditor types.

Investor Backing & Capital Strength: Funding announcements show Marble Health raised a $15.5M Series A in October 2025 led by Costanoa with participation from Town Hall Ventures and Khosla Ventures, signaling strong investor support. Company and investor communications indicate this capital is earmarked to scale operations, expand partnerships, and grow the team.

Market Expansion: Company updates indicate launches beyond New York into states like Ohio and New Jersey, pointing to a widening geographic footprint. Public materials also highlight school partnerships and rising therapy-session volumes since launch, consistent with expansion.

Strong Hiring & Retention: Open roles across growth, operations, and product on company and third‑party job boards indicate active team growth. Leadership posts describe go‑to‑market hiring momentum ahead of school years, suggesting sustained scaling efforts.

Strong Revenue Growth: Parent-company disclosures indicate year-over-year increases in paying users, ARPU, and segment revenue, with Brigit contributing materially to quarterly results. Management commentary references plans to increase marketing to drive further user growth under Upbound’s ownership.

Investor Backing & Capital Strength: Corporate backing is evidenced by Upbound’s completed acquisition and continued positioning of Brigit as a growth pillar with explicit investment and guidance. The parent’s earnings materials underscore ongoing support and resources for scaling.

Product Line Growth: Expansion beyond core advances includes higher adoption of premium tiers and marketplace offers, plus a measured rollout of a line‑of‑credit alongside budgeting and credit‑building tools. These developments align with rising monetization per user highlighted in recent updates.

Strong Hiring & Retention: Active hiring signals are evident with multiple recent postings across Operations, Engineering, Product, RCM, and Partnerships and a visible “We’re Hiring!” banner. Feedback suggests team size and social followership on LinkedIn are consistent with recent headcount expansion.

Market Expansion: The company markets Medicare-covered virtual psychotherapy “across all 50 states,” indicating a national footprint rather than a limited pilot. Self-described service to “thousands of patients” across many states further reinforces expanding reach.

Innovation-Driven Growth: The organization emphasizes an AI-native platform with real-time clinical insights and clinical copilots to scale care delivery and efficiency. This technology-forward posture supports growth in virtual operations for older adults.

Investor Backing & Capital Strength: GV led a $28.1M round in February 2023 to scale firsthand’s Medicaid-focused SMI model and multi‑state operations. This capital provides runway supporting ongoing activity despite subsequent turbulence.

Market Expansion: Operations span multiple states (e.g., Florida, Ohio, Michigan, Virginia, Washington) with active postings in 2026, indicating selective growth and continuation in targeted markets. Company materials and social updates point to stabilization and focused re‑entry after 2025 cuts.

Strategic Partnerships: The model centers on payer partnerships in Medicaid, and firsthand is a contracted provider with Molina, aligning offerings with managed‑care needs. Such plan relationships underpin access to attributed lives and contract‑driven revenue.

Profitability: Profitability is supported by strong adjusted EBITDA margins, with 2025 at roughly one‑third of revenue and Q1 2026 near that level as tighter cost control held despite mix shifts. This indicates stable profit generation during a transition toward newer businesses.

Product Line Growth: Product lines tied to Pharma Direct and condition‑specific subscriptions are expanding rapidly, with Pharma Direct accelerating year over year and subscriptions returning to growth in Q1 2026. This momentum reflects successful scaling of newer offerings like GLP‑1 weight‑loss programs.

Diversified Revenue Streams: The business is leaning into Pharma Direct and rebuilding subscriptions to offset softness in core prescription transactions over time. Management explicitly positioned Pharma Direct as central to future growth, broadening the mix beyond discount‑card transactions.

Market Expansion: Playground markets itself as serving 5,000+ child‑care programs and appears in current startup ecosystem materials (e.g., the 2026 GSV Cup Look Book), indicating broader visibility and reach. Recently published customer stories on the site suggest ongoing adoption across providers.

Innovation-Driven Growth: The public changelog documents regular releases through April 20, 2026, including a new dialer and AI‑suggested tasks, consistent with an actively maintained platform. References to AI‑enabled capabilities reinforce an emphasis on product innovation.

Strong Hiring & Retention: The company’s careers page lists open roles with a structured recruiting process, and Built In NYC’s profile notes continued hiring alongside revenue growth. Active recruiting supports the narrative of a scaling organization.

Investor Backing & Capital Strength: Recent Series B financing led by a tier‑one investor and total funding of $50M indicate a strong capital position to support scaling. Announced plans link this capital to product and market expansion through 2025–2026.

Market Expansion: Public materials describe serving large patient volumes across dozens of states and adding specialties beyond behavioral health into areas like home health, long‑term care, and substance use care. Partnerships and broader specialty positioning suggest widening distribution and reach.

Strong Hiring & Retention: Active job postings into 2026 and multiple open roles point to ongoing team expansion aligned with go‑to‑market and operations scale‑up. Company and aggregator pages consistently show a growing employee band.

Market Expansion: Public materials describe broadened operations across major U.S. hubs and international cities, with additional California expansion plans noted in March 2026 coverage. Company channels also reference global pickup coverage across North America, EMEA, and APJ.

Product Line Growth: Recent updates highlight expanded Device Retrievals and a unified, enterprise‑grade lifecycle platform. These feature additions indicate ongoing investment to address a wider range of assets and workflows.

Strong Hiring & Retention: Active recruitment for senior go‑to‑market roles and an updated headcount listing (e.g., 120 employees on Built In in June 2026) signal team expansion. Job descriptions and public posts depict a profitable, rapidly growing business consistent with scaling talent needs.

Investor Backing & Capital Strength: Recent late‑stage financing of $150M in March 2026 and a reported ~$3B valuation signal strong external capital support and balance‑sheet flexibility. Multiple reputable outlets and independent trackers corroborate the funding milestone and late‑stage status.

Strong Revenue Growth: Trade coverage and company statements cite approximately a $1B annual revenue run rate around the Series D, indicating rapid top‑line expansion. These figures are directional but echoed across multiple reputable sources.

Strategic Partnerships: Expansion of integrations with health plans and new employer offerings points to deepening commercial relationships beyond direct‑to‑consumer. Reports describe broad insurer participation and expanded enterprise distribution.